Nicox posts second quarter revenue

Nicox reported net revenue of 5.2 million euros in the second quarter of 2019 compared with net revenue of 0.2 million euros in 2018’s second quarter, according to a press release.

The company had cash and cash equivalents of 17.3 million euros as of June 30, which does not include an upfront payment of 2 million euros from Ocumension or a milestone payment of $3 million from Eyevance received in July.

Operational highlights for the quarter include a 17% increase in prescriptions for Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) compared with 2019’s first quarter and a 161% increase compared with 2018’s second quarter.

Nicox reported net revenue of 5.2 million euros in the second quarter of 2019 compared with net revenue of 0.2 million euros in 2018’s second quarter, according to a press release.

The company had cash and cash equivalents of 17.3 million euros as of June 30, which does not include an upfront payment of 2 million euros from Ocumension or a milestone payment of $3 million from Eyevance received in July.

Operational highlights for the quarter include a 17% increase in prescriptions for Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) compared with 2019’s first quarter and a 161% increase compared with 2018’s second quarter.